Strides Pharma awaiting govt nod for Favipiravir, says CEO R Ananthanarayanan

"Our focus is ensuring that we are able to get approvals for all the
necessary studies and data in India. We will be able to provide the
drug once the Indian approvals come through. This is our main
bottleneck now," said R Ananthanarayanan.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/strides-pharma-awaiting-govt-nod-for-favipiravir-says-ceo-r-ananthanarayanan/articleshow/75463029.cms

Comments

Popular posts from this blog

Biotecnika Times Newsletter 25.10.2021 Tata Innovation Fellowship 2021, NCCS PhD Admission

TIGS-CI Biological Sciences Research Assistant Recruitment, Apply Online